Accessibility Menu
Kezar Life Sciences logo

Kezar Life Sciences(NASDAQ) KZR

This security has been delisted. This page is retained for historical reference.

Kezar Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 7.292026-05-08
Kezar Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.55%USD 7.332026-05-01
1 month-1.22%USD 7.382026-04-08
3 month+19.12%USD 6.122026-02-06
Year to date+15.9%USD 6.292025-12-31
1 year+76.94%USD 4.122025-05-08
3 year-71.96%USD 26.002023-05-09
5 year-86.98%USD 56.002021-05-07
Since inception-95.89%USD 177.502018-06-21

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

KZR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-58.35%

Return on Capital

-72.20%

Return on Assets

-66.52%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$176.00K

Operating Income

-$42.01M

EBITDA

-$31.73M

Operating Cash Flow

-$42.03M

Capital Expenditure

$0.00

Free Cash Flow

-$42.03M

Cash & ST Invst.

$66.23M

Total Debt

$1.35M

Kezar Life Sciences Performance Analysis

Kezar Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 7,000,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Kezar Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Kezar Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.13-2.2%
20232023-12-31USD -14.0438.6%
20242024-12-31USD -11.49-18.2%
20252025-12-31USD -7.66-33.3%
Kezar Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3017.6%
Q32025-09-3018.2%
Q42025-12-31-30.1%
Q12026-03-3160.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

55

N/A

Net Income

-$5.76M

+65.2%

EBITDA

$47.00K

+100.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$66.23M

-42.1%

Total Debt

$1.35M

-90.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.35M

-84.8%

Return on Assets

-66.52%

N/A

Return on Invested Capital

-64.39%

N/A

Free Cash Flow

-$7.45M

+56.7%

Operating Cash Flow

-$7.45M

+56.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TPSTTempest Therapeutics, Inc.
$0.89+1.38%
FGENFibroGen, Inc.
$9.07-1.63%
OKUROnKure Therapeutics, Inc.
$4.10+1.99%
ALGSAligos Therapeutics, Inc.
$4.75+3.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.